GRANOCYTE

Reason for request

Clinical Benefit

Substantial

The actual benefit of Granocyte in all indications is substantial.

Clinical Added Value

moderate

Mobilisation of peripheral blood progenitor cells in healthy donors prior to allogenic transplantation Granocyte shares the IAB III rating as Neupogen.

Comments without ASMR value

Mobilisation of peripheral blood progenitor cells in patients prior to autologous transplantation and Reduction in duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation, and at increased risk of severe, prolonged neutropenia The Committee considered that both growth factors, including Granocyte, still have an important role to play and occupy the same place in the treatment strategy.